Pko Investment Management Joint Stock CO Incyte Corp Transaction History

Pko Investment Management Joint Stock CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Mar 13, 2025	SELL	$57.33 - $68.61 $257,985 - $308,745	-4,500 Reduced 42.86%	6,000 $397 Million
Q2 2024 Mar 13, 2025	SELL	$51.18 - $63.75 $204,720 - $255,000	-4,000 Reduced 40.0%	6,000 $364 Million
Q1 2024 Mar 13, 2025	BUY	$56.55 - $66.59 $565,500 - $665,900	10,000 New	10,000 $572 Million
Q4 2023 Mar 13, 2025	BUY	$52.16 - $64.19 $547,680 - $673,995	10,500 New	10,500 $659 Million
Q3 2023 Mar 13, 2025	SELL	$57.77 - $65.93 $202,195 - $230,755	-3,500 Reduced 25.0%	10,500 $607 Million
Q2 2023 Mar 13, 2025	BUY	$60.95 - $75.51 $548,550 - $679,590	9,000 Added 180.0%	14,000 $872 Million
Q1 2023 Mar 13, 2025	BUY	$70.23 - $86.01 $175,575 - $215,025	2,500 Added 100.0%	5,000 $361 Million
Q2 2022 Mar 13, 2025	SELL	$66.18 - $83.18 $231,630 - $291,130	-3,500 Reduced 58.33%	2,500 $190 Million
Q1 2022 Mar 13, 2025	SELL	$66.02 - $79.71 $924,280 - $1.12 Million	-14,000 Reduced 70.0%	6,000 $477 Million
Q4 2021 Mar 13, 2025	BUY	$63.34 - $74.11 $1.27 Million - $1.48 Million	20,000 New	20,000 $1.47 Billion

709

189M

909K

489K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $13.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Pko Investment Management Joint Stock CO, based on Form 13F filings with the SEC.

Stay updated on Pko Investment Management Joint Stock CO with notifications on news.